Serving as a negative regulator of T-cell-mediated antitumor immunity, VTCN1 can inhibit T cell activation and cytokine secretion, and regulate cytotoxic T lymphocytes (CTLs) during tumor progression (67). This evidence concerns the gene VTCN1 and neoplasm.